The US Centers for Medicare & Medicaid Services (CMS) has announced the selection of 15 high-cost prescription drugs covered under Medicare Part D and, for the first time, drugs payable under Medicare Part B for the third cycle of the Medicare Drug Price Negotiation Program. Under this program, CMS directly negotiates the prices of certain high expenditure, single source drugs without generic or biosimilar competition. CMS is also releasing a list of 50 top negotiation-eligible drugs based on combined expenditures under Medicare Parts B and D. The drugs selected for the third cycle represent the top 15 highest-spending drugs on this list. “The publication of the list of top 50 negotiation-eligible drugs evidences CMS’ commitment to transparency,” said CMS Deputy Administrator and Director of Medicare Chris Klomp. Of note, CMS also considers other information, such as costs associated with research and development as well as current costs of production and distribution for selected drugs.